Journal
LANCET
Volume 388, Issue 10058, Pages 2403-2415Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30053-8
Keywords
-
Categories
Funding
- Merck Serono
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Shire
- Ipsen
- Sandoz
- Merck
- Eli Lilly
- Novo Nordisk Fonden [NNF15OC0015922] Funding Source: researchfish
Ask authors/readers for more resources
Hypopituitarism refers to deficiency of one or more hormones produced by the anterior pituitary or released from the posterior pituitary. Hypopituitarism is associated with excess mortality, a key risk factor being cortisol deficiency due to adrenocorticotropic hormone (ACTH) deficiency. Onset can be acute or insidious, and the most common cause in adulthood is a pituitary adenoma, or treatment with pituitary surgery or radiotherapy. Hypopituitarism is diagnosed based on baseline blood sampling for thyroid stimulating hormone, gonadotropin, and prolactin deficiencies, whereas for ACTH, growth hormone, and antidiuretic hormone deficiency dynamic stimulation tests are usually needed. Repeated pituitary function assessment at regular intervals is needed for diagnosis of the predictable but slowly evolving forms of hypopituitarism. Replacement treatment exists in the form of thyroxine, hydrocortisone, sex steroids, growth hormone, and desmopressin. If onset is acute, cortisol deficiency should be replaced first. Modifications in replacement treatment are needed during the transition from paediatric to adult endocrine care, and during pregnancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available